$2.39
+0.04 (+1.70%)
Open$2.36
Previous Close$2.35
Day High$2.55
Day Low$2.33
52W High$6.46
52W Low$3.90
Volume—
Avg Volume421.3K
Market Cap106.88M
P/E Ratio41.10
EPS$0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+124.7% upside
Current
$2.39
$2.39
Target
$5.37
$5.37
$3.28
$5.37 avg
$6.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 59.48M | 62.40M | 61.85M |
| Net Income | -10,809,084 | -13,759,336 | -10,609,098 |
| Profit Margin | -18.2% | -22.1% | -17.2% |
| EBITDA | -13,281,170 | -15,040,886 | -15,866,697 |
| Free Cash Flow | -10,468,769 | -13,384,851 | -9,996,517 |
| Rev Growth | +6.2% | +12.2% | +11.1% |
| Debt/Equity | 0.58 | 0.54 | 0.60 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |